These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35988656)

  • 1. Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.
    Jahn A; Rump A; Widmann TJ; Heining C; Horak P; Hutter B; Paramasivam N; Uhrig S; Gieldon L; Drukewitz S; Kübler A; Bermudez M; Hackmann K; Porrmann J; Wagner J; Arlt M; Franke M; Fischer J; Kowalzyk Z; William D; Weth V; Oster S; Fröhlich M; Hüllein J; Valle González C; Kreutzfeldt S; Mock A; Heilig CE; Lipka DB; Möhrmann L; Hanf D; Oleś M; Teleanu V; Allgäuer M; Ruhnke L; Kutz O; Knurr A; Laßmann A; Endris V; Neumann O; Penzel R; Beck K; Richter D; Winter U; Wolf S; Pfütze K; Geörg C; Meißburger B; Buchhalter I; Augustin M; Aulitzky WE; Hohenberger P; Kroiss M; Schirmacher P; Schlenk RF; Keilholz U; Klauschen F; Folprecht G; Bauer S; Siveke JT; Brandts CH; Kindler T; Boerries M; Illert AL; von Bubnoff N; Jost PJ; Metzeler KH; Bitzer M; Schulze-Osthoff K; von Kalle C; Brors B; Stenzinger A; Weichert W; Hübschmann D; Fröhling S; Glimm H; Schröck E; Klink B
    Ann Oncol; 2022 Nov; 33(11):1186-1199. PubMed ID: 35988656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study.
    Hutchcraft ML; Zhang S; Lin N; Pickarski JC; Belcher EA; Wei S; Bocklage T; Miller RW; Villano JL; Cavnar MJ; Kim J; Arnold SM; Ueland FR; Kolesar JM
    JCO Precis Oncol; 2024 Jan; 8():e2300266. PubMed ID: 38295319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.
    Samadder NJ; Riegert-Johnson D; Boardman L; Rhodes D; Wick M; Okuno S; Kunze KL; Golafshar M; Uson PLS; Mountjoy L; Ertz-Archambault N; Patel N; Rodriguez EA; Lizaola-Mayo B; Lehrer M; Thorpe CS; Yu NY; Esplin ED; Nussbaum RL; Sharp RR; Azevedo C; Klint M; Hager M; Macklin-Mantia S; Bryce AH; Bekaii-Saab TS; Sekulic A; Stewart AK
    JAMA Oncol; 2021 Feb; 7(2):230-237. PubMed ID: 33126242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study.
    Nacer DF; Vallon-Christersson J; Nordborg N; Ehrencrona H; Kvist A; Borg Å; Staaf J
    Genome Med; 2023 Apr; 15(1):25. PubMed ID: 37060015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches.
    Roggia C; Armeanu-Ebinger S; Gschwind A; Seibel-Kelemen O; Hertler S; Faust U; Liebmann A; Haack TB; Neumann M; Bonzheim I; Forschner A; Kopp HG; Herster F; Hartkopf A; Bitzer M; Malek NP; Brecht IB; Ruhm K; Möller Y; Löwenheim H; Ossowski S; Rieß OH; Schroeder C
    Eur J Cancer; 2023 Jan; 179():48-55. PubMed ID: 36495689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers.
    Hao S; Zhao X; Fan Y; Liu Z; Zhang X; Li W; Yuan H; Zhang J; Zhang Y; Ma T; Tao H
    Cancer Med; 2023 Sep; 12(17):18394-18404. PubMed ID: 37610374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics.
    Koster R; Schipper LJ; Giesbertz NAA; van Beek D; Mendeville M; Samsom KG; Rosenberg EH; Hogervorst FBL; Roepman P; Boelens MC; Bosch LJW; van den Berg JG; Meijer GA; Voest EE; Cuppen E; Ruijs MWG; van Wezel T; van der Kolk L; Monkhorst K
    Genet Med; 2024 Feb; 26(2):101032. PubMed ID: 38006283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic applications of germline testing for cancer predisposition genes in Asia in the real world.
    Cheo SW; Ong PY; Ow SGW; Chan GHJ; Tan DSP; Lim YW; Kong HL; Wong ALA; Lim SE; Walsh RJ; Wong ASC; Low JJH; Ngoi NYL; Lim JSL; Lee SC
    ESMO Open; 2024 Jun; 9(6):103482. PubMed ID: 38833967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer.
    Heald B; Mokhtary S; Nielsen SM; Rojahn S; Yang S; Michalski ST; Esplin ED
    Gynecol Oncol; 2022 Aug; 166(2):344-350. PubMed ID: 35691755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
    Vanni I; Pastorino L; Andreotti V; Comandini D; Fornarini G; Grassi M; Puccini A; Tanda ET; Pastorino A; Martelli V; Mastracci L; Grillo F; Cabiddu F; Guadagno A; Coco S; Allavena E; Barbero F; Bruno W; Dalmasso B; Bellomo SE; Marchiò C; Spagnolo F; Sciallero S; Berrino E; Ghiorzo P
    J Transl Med; 2024 May; 22(1):462. PubMed ID: 38750555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision oncology based on omics data: The NCT Heidelberg experience.
    Horak P; Klink B; Heining C; Gröschel S; Hutter B; Fröhlich M; Uhrig S; Hübschmann D; Schlesner M; Eils R; Richter D; Pfütze K; Geörg C; Meißburger B; Wolf S; Schulz A; Penzel R; Herpel E; Kirchner M; Lier A; Endris V; Singer S; Schirmacher P; Weichert W; Stenzinger A; Schlenk RF; Schröck E; Brors B; von Kalle C; Glimm H; Fröhling S
    Int J Cancer; 2017 Sep; 141(5):877-886. PubMed ID: 28597939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients.
    Satake T; Kondo S; Tanabe N; Mizuno T; Katsuya Y; Sato J; Koyama T; Yoshida T; Hirata M; Yamamoto N
    Cancer Res Commun; 2023 Nov; 3(11):2302-2311. PubMed ID: 37916805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study.
    Uson Junior PL; Kunze KL; Golafshar MA; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Faigel DO; Fukami N; Pannala R; Barrus K; Mountjoy L; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T; Samadder NJ
    Cancer Prev Res (Phila); 2022 Feb; 15(2):121-128. PubMed ID: 34782326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substantial batch effects in TCGA exome sequences undermine pan-cancer analysis of germline variants.
    Rasnic R; Brandes N; Zuk O; Linial M
    BMC Cancer; 2019 Aug; 19(1):783. PubMed ID: 31391007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.
    Berchuck JE; Boiarsky D; Silver R; Sunkara R; McClure HM; Tsai HK; Siegmund S; Tewari AK; Nowak JA; Lindeman NI; Rana HQ; Choudhury AD; Pomerantz MM; Freedman ML; Van Allen EM; Taplin ME
    JCO Precis Oncol; 2022 Aug; 6():e2200329. PubMed ID: 36103646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parents' expectations, preferences, and recall of germline findings in a childhood cancer precision medicine trial.
    McGill BC; Wakefield CE; Tucker KM; Daly RA; Donoghoe MW; Vetsch J; Warby M; Fuentes-Bolanos NA; Barlow-Stewart K; Kirk J; Courtney E; O'Brien TA; Marshall GM; Pinese M; Cowley MJ; Tyrrell V; Deyell RJ; Ziegler DS; Hetherington K
    Cancer; 2023 Nov; 129(22):3620-3632. PubMed ID: 37382186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Universal Genetic Testing vs. Guideline-Directed Testing for Hereditary Cancer Syndromes Among Traditionally Underrepresented Patients in a Community Oncology Program.
    Jones JC; Golafshar MA; Coston TW; Rao R; Wysokinska E; Johnson E; Esplin ED; Nussbaum RL; Heald B; Klint M; Barrus K; Uson PL; Nguyen CC; Colon-Otero G; Bekaii-Saab TS; Dronca R; Kunze KL; Samadder NJ
    Cureus; 2023 Apr; 15(4):e37428. PubMed ID: 37181954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translating Germline Cancer Risk into Precision Prevention.
    Yurgelun MB; Chenevix-Trench G; Lippman SM
    Cell; 2017 Feb; 168(4):566-570. PubMed ID: 28187278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Predisposition Sequencing Reporter (CPSR): A flexible variant report engine for high-throughput germline screening in cancer.
    Nakken S; Saveliev V; Hofmann O; Møller P; Myklebost O; Hovig E
    Int J Cancer; 2021 Dec; 149(11):1955-1960. PubMed ID: 34310709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer.
    Rebhan K; Stelzer PD; Pradere B; Rajwa P; Kramer G; Hofmann B; Resch I; Yurdakul O; Laccone FA; Bujalkova MG; Smogavec M; Tan YY; Ristl R; Shariat SF; Egger G; Hassler MR
    World J Urol; 2023 Aug; 41(8):2091-2097. PubMed ID: 37528288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.